Kort fortalt: STORY: A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation.It's rattling investors despite calls for stronger leadership at the drugmaker behind weight-loss treatment Wegovy.Once Europe's most valuable firm thanks to the blockbuster obesity drug, Novo Nordisk has stumbled in the last year.Slowing sales and intensifying competition from U.S. rival Eli Lilly have eroded its market share.The Novo Nordisk Foundation holds more than three-quarters of the firm's voting shares.This week it pushed out Novo's board chairman and independent members for not acting quickly enough to stem the decline in its key U.S. market.Foundation chair Lars Rebien Sorensen – a former long-time Novo chief executive – will also become the company board chairman.The
Baggrund: Når et analysehus ændrer kursmål, afspejler det en opdateret vurdering af indtjening, risici og markedsvilkår. Kursmål er ikke en garanti for afkast, men et pejlemærke.
- Analytiker justerer kursmål.
- Signal om ændret vurdering af indtjening/risiko.
- Kursmål er estimat – kortsigtet reaktion kan afvige.
- Relevans for danske investorer og OMXC25.
Kilde: finance.yahoo.com
Dette er ikke investeringsrådgivning.
Kilde: finance.yahoo.com
Dette er ikke investeringsrådgivning.
Graf/oversigt indsættes her ved senere opdatering.
- finance.yahoo.com · 2025-10-25
- finance.yahoo.com · 2025-10-25


